BioCentury on BioBusiness,
Tools & Techniques
IL-2 in AIDS
Monday, July 17, 2000
Given the suppression of viral load in AIDS patients that is being achieved by highly active antiretroviral therapy (HAART), attention is turning to stimulation of the immune system to restore immune function and reduce the latent viral reservoir in these patients. One possibility is Chiron Corp.'s Proleukin aldesleukin recombinant human interleukin-2 (IL-2), an immune stimulant that has shown positive Phase II data in increasing CD4 T cell counts while sustaining viral load reduction.
Proleukin is in two ongoing Phase III trials in combination with HAART - CHIR's 1400-patient SILCAAT trial and the NIH's 4000-patient ESPRIT trial. A BLA for the AIDS indication is not expected until CHIR has final results from its trial, which are due in 2006. Given that Proleukin is already marketed for metastatic renal carcinoma and metastatic melanoma, the product may receive off-label use before then. However physicians may have concerns about side effects with IL-2 therapy in AIDS patients.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]